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A B S T R A C T
Bone morphogenetic proteins (BMPs) are cytokines which are important for kidney homeostasis but also have role in
the some renal diseases and renal cell carcinoma (RCC)1–5. In the last three decades incidence of RCC was constantly in-
creased and the role of different molecular biomarkers in RCC is explored1. We analyzed expression of BMP-7, their re-
ceptors (BMPR-IA, BMPR-IB, BMPR-II) and proteins of their signaling pathway (pSmad1/5/8) in sixteen renal cancer
samples and paired normal tissue. Tissue samples were analyzed by immunohistochemistry and Western blot. BMP-7,
BMP receptors and pSmad1/5/8 were expressed in all structures of normal kidney but dominantly in the proximal tubu-
lar cells. In the cancer samples their expression was also noticed. Comparison of BMPs between different tissue showed
increased expression of BMPR-IB and pSmad 1/5/8 and decreased expression of BMP-7 and BMPR-II in RCC compared
to normal kidney. BMPR-IA was detected with immunohistochemistry but with Western blot attenuated signal was pre-
sented. BMP-7, BMP receptors and pSmad1/5/8 were showed in normal kidney and RCC. Detected alterations of BMP-7,
BMP receptors and pSmad expression in RCC suggested their possible role in tumorigenesis of kidney cancer.
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Introduction
Bone morphogenetic proteins (BMPs) are members of
transforming growth factor b (TGF-b) superfamily1.
They are classified according to their amino acid seque-
nces into the following groups: 1) BMP-2 and BMP-4; 2)
BMP-3 and BMP-3b; 3)BMP-5, BMP-6, BMP-7, BMP-8; 4)
BMP-9, BMP-10; 5) BMP12, BMP-13 and BMP-14; and 6)
BMP-11 and GDF-82. Like others members of TGF-b
superfamily they transfer signal in the cell by two type of
receptors: type I and type II. Type I receptors can be di-
vided on the ALK-2 (Act-RI), ALK-3 (BMPR-IA), ALK-6
(BMPR-IB) and type II on the BMPR-II, ActR-II and
ActR-IIB3. Inside the cell signal travels by Smad signal-
ing pathway (dominant) and through mitogene activated
protein-kinases (MAPKs), which include p384. Activated
receptor complexes recruit and phosphorylate Smad 1, 5
and 8, which also binds costimulatory protein Smad 4.
Smad complexes then translocate into the nucleus where
they act as transcription factors1.
BMPs have important role in cellular differentiation,
proliferation, apoptosis and morphogenesis5. In the pre-
natal life BMPs are involved in the development of many
organs and tissues like skeleton, kidney, eyes, heart5.
BMP-7 have essential role in kidney development5. After
the birth BMPs are involved in maintaining of homeosta-
sis in some organs like kidneys and have a role in patho-
physiology of several diseases including osteoporosis, ar-
thritis, kidney diseases, pulmonary hypertension, cere-
brovascular diseases and cancer6,7.
Renal cell carcinoma (RCC) accounting for about 3%
of all adult cancers with the highest incidence in the
more developed countries8. Kidney cancer is important
urologic cancer because of its relative high lethality and
increasing incidence. RCC is one of the most aggressive
cancers among urologic malignancies and approximately
30% patients undergoing radical nephrectomy will de-
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velop metastases9. The earlier discovery and increased
detection has occurred since the advent of ultrasono-
graphy, computed tomography and magnetic resonance
imaging (MRI)10. According to the 2004 WHO classifica-
tion there are three main histopathologic subtypes with
distinct clinical behavior: conventional (clear cell), papil-
lary and chromophobe RCC11. Prognosis of patients with
RCC is predicted by TNM stage, Fuhrman nuclear grad-
ing system and histological subtype12.
Recent researches of BMPs showed their important
role in carcinogenesis of different cancers like prostate,
breast, lung and colon13–15. The role of BMP in the kidney
cancer is still under the investigation16–26.
Since, BMPs have role in tumorigenesis of different
carcinomas, we investigated the expression pattern of
BMP-7, BMPR-IA, BMPR-IB, BMPR-II and phosphory-




Sixteen renal cancer samples and matched controls of
normal tissue (taken far from the tumor site) were taken
immediately after nephrectomy and frozen in liquid ni-
trogen at –80 °C. For immunohistochemistry same tissue
samples were fixed in 4% buffered formalin. Tissue sam-
ples were acquired from the Department of Urology, Uni-
versity Hospital Center in Rijeka, Croatia. Hospital and
university local ethical committee approved the study.
Written informed consent and approval were obtained
from all patients. Out of 16 patients 8 were diagnosed
with clear cell carcinoma, other 8 had non-clear cell types
and among them 6 had papillary and 2 chromophobe
type. Pathological stage and tumor grade were diagnosed
according to TNM classification and the Fuhrman nu-
clear grading status.
Tissue microarrays construction
Tissue microarrays containing samples of 16 tumors
and paired normal tissue were constructed. Five core bi-
opsies with a diameter of 2 mm were obtained from each
tumor from a histologically representative area.
Immunohystochemistry
Immunohystochemistry was carried out on 3 µm for-
malin-fixed and paraffin-embedded kidney tissue sec-
tions. Sections were deparaffinized and treated with 0.3%
hydrogen peroxidase for 10 minutes at room tempera-
ture to block endogenous peroxidase. Slides were incu-
bated with phosphate-buffered saline (PBS) containing
10% bovine serum albumin for 30 minutes at room tem-
perature to avoid nonspecific binding. In the following
step the sections were incubated with goat polyclonal an-
tibody raised against human BMP-7, BMPRI-A, BMPRI-
-B and BMPR-II (all diluted to 1:100, from Santa Cruz
Biotechnology, California, USA), left overnight at 4 °C.
For pSmad 1/5/8 (Cell Signaling, Massachusetts, USA)
staining we performed antigen retrieval in 0.1M citric
acid, pH 7.2, for 15 minutes in microwave and then ap-
plied antibody 1:100 dilution overnight at 4°C. All slides
were incubated with horseradish peroxidase (HRP)-con-
jugated rabbit anti-goat secondary antibody (DakoCyto-
mation, Glostrup, Denmark) and ABC reagent for 30
minutes at room temperature. The specimens were wa-
shed with PBS three times for 10 minutes after each step
and signal was detected using diaminobenzidine (DAB).
Finally, sections were counterstained with hematoxylin.
As a control, PBS was used in place of the primary anti-
body.
Western blot analysis
Tissue was homogenized in lysis buffer (1% Triton
x-100, 0.5 Sodium deoxycholate, 0.1% SDS, 0.1 mM phe-
nylmethylsulfonyl fluoride) and stored at 4 °C for 30 min-
utes. After centrifugation at 13.000 rpm at 4 °C for 30
minutes, supernatant was collected and protein concen-
tration determined by Bradford method. Samples were
boiled for 5 minutes and equal amount of total protein
from each sample (40 mg) were loaded and electropho-
resed on 12 % SDS polyacrilamide gel (200 V, 35 min-
utes). After electrophoresis, the proteins were trans-
ferred to nitrocellulose membrane and incubated with
5% skim milk in TBS containing 0.05% Tween-20 for 60
minutes at room temperature. The primary antibody for
BMP-7, BMPRI-A, BMPRI-B, BMPR-II (Santa Cruz Bio-
technology, California, USA) and pSmad 1/5/8 (Cell Sig-
naling, Massachusetts, USA) was prepared at 1:200 dilu-
tion at 4 °C overnight, followed by a horseradish pero-
xidase conjugated secondary antibody for 60 minutes at
room temperature. The membranes were washed with
TBS-T three times for 15 minutes after each step. Im-
munoreactive bands were detected using enhanced che-
miluminescence reagents (ECL; Amersham, Buckingham-
shire, UK) and visualized using Kodak BioMax MS film
(Sigma-Aldrich Corporation, Missouri, USA). As internal
loading control the blots were re-probed for b-actin (San-
ta Cruz Biotechnology, California, USA). The signal in-
tensity of the protein product was quantified by den-
sitometry (Kodak Image Station 440, LabImage, Halle,
Germany). The relative expression level of the BMP-7,
BMP receptors and pSmad1/5/8 was calculated as the ra-
tio between their expression and expression of b-actin
and multiplied by one hundred.
Statistics
Statistical analysis was conducted using software,
Statistica 6.1 (StatSoft Inc., Tulsa, USA). Results were
presented as mean (X)±standard error of mean (SEM).
Student t-test was used to compare relative expression of
different proteins between normal kidney and RCC. Dif-
ference were considered statistically significant with
p<0.05.
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Results
In normal kidney tissue BMP-7 had strong expression
in the cytoplasm of proximal tubular cells. Distal tubular
cells had much lower expression of BMP-7 and glomeruli
had scarce expression of BMP-7. The same localization of
immunoreactive staining was noticed when we applied
BMPR-IA, BMPR-IB and BMPR-II antibody. BMPR-IA
intensity of staining was very weak. BMP signaling path-
way was also confirmed in normal kidney tissue through
pSmad 1/5/8 positive reaction observed as cytoplasmatic
and nuclear staining. Distribution of expression was sim-
ilar as for BMP-7.
In renal carcinoma BMP-7 and receptors were de-
tected as diffuse staining in cytoplasm of cells, both in
clear cell carcinoma and non clear cell types. Also, pSmad
1/5/8 positivity in carcinoma was localized in cytoplasm
and nucleus, confirming that BMP signaling pathway is
active both in normal and carcinoma affected tissue.
Western blot analysis detected BMP-7, BMPR-IB,
BMPR-II and pSmad 1/5/8 in normal kidney and in RCC
(Figure 1). Their expression was present in all types of
RCC (data not shown). In tumor samples expression of
BMPR-IB and pSmad 1/5/8 were increased compared to
normal tissue (Table 1). BMP-7 and BMPR-II were in-
creased in healthy renal parenchyma. BMPR-IA was not
presented with adequate signal in both type of tissue and
their analysis was not possible. BMP-7 has lower expres-
sion in cancer tissue (regarding subtype) than in healthy
kidney. Differences in relative expression between BMP-
-7, BMPR-IB, BMPR-II and pSmad 1/5/8 in normal kid-
ney and RCC were not statistically significant (Table 1).
Discussion and Conclusion
BMP-7 is a member of the TGF-b superfamily and
plays important role during kidney development but also
in adult kidney physiology and pathophysiology of renal
diseases. In fetal period BMP-7 is expressed multifocally
within the embryonic metanephric mesenchyme and ure-
teric bud epithelia5. BMP-7 knockout mice die owing to
renal failure perinatally as a result of severe kidney
dysplasia5. In normal rat kidney the highest expression
of BMP-7 mRNA is found in tubular epithelial cells of the
outer medulla and in glomerular epithelial cells. Other
parts of nephron had lower expression18. Also, high BMP-
-7 mRNA expression is located in adventitia of renal ar-
teries as in epithelial cell layer of renal pelvis and the
ureter18. The expression of BMP receptors is found in the
cortex area (glomeruli, convoluted tubule epithelium)
and in medulla (collecting ducts)18,19. Receptor expres-
sion was higher in the kidney cortex than in medulla19.
Wetzel et al. found that in the human adult normal kid-
ney BMP-7 is predominantly localized to the distal ne-
phron: epithelia of distal tubule and collecting ducts20.
Expression of phospho-Smads1/5/8 was colocalized with
expression of BMP-720.
Our data indicated that in the normal human kidney
tissue BMP-7 was mainly localized in cytoplasm of proxi-
mal tubular cells. The same localization was found for
BMPR-IA, BMPR-IB, BMPR-II and pSmad1/5/8. The re-
sults of our investigations are partly different from the
work of Wetzel et al. where BMP-7 and their receptors
are found mostly in the distal nephron20. Kwak et al. con-
firmed, as in our study, dominant expresion of BMP-7 in
the proximal tubular cells17. The possible explanation is
that expression of BMP-7 can vary in the kidney speci-
mens because of influence of different factors: environ-
mental, genetics or disease. We must mention that our
normal kidney specimens were from the kidney with
RCC (same as in the other studies). Also investigation on
greater number of kidney specimens is mandatory (we
examined sixteen and Wetzel et al. only six normal speci-
mens)20. In only one study immunohistochemistry was
used with microdissection of renal tissue to establish ex-
act localization20. Multi-institutional study with greater
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TABLE 1










Normal kidney 160.0±48.9 41.0±16.1 89.2±16.7 78.8±20.1
RCC 107.6±53.2 66.1±30.3 63.4±20.4 118.8±30.2
p-value 0.482 (NS) 0.486 (NS) 0.350 (NS) 0.297 (NS)



































Fig. 1. Expression of BMP-7, BMPR-IB, BMPR-II and pSmad1/
5/8 in normal kidney and renal cell cancer (RCC). Term BMPs
included BMP-7, BMPR-IB, BMPR-II and pSmad1/5/8.
number of healthy renal parenchyma samples and with
microdissection of tissue will potentially show localiza-
tion of BMPs and their receptors in the normal kidney.
When we analyzed relative expressions of BMPs it is
obvious that BMP-7 have highest expression, especially
in the normal kidney. This is in concordance with obser-
vation that BMP-7 plays important role in the human
kidney1,2,5.
In the recent years dysregulation of BMP signaling in
carcinogenesis has been linked to different types of can-
cers. Both up- and down-regulation of BMPs and their
receptors have been reported in association with the pro-
gression of a variety of solid tumors. For example BMP-4
is increased in colonic adenocarcinoma, BMP-2 is highly
overexpressed in lung cancers, BMP-2, BMPR-IA and
BMPR-II are all up-regulated in pancreatic cancer sam-
ples, BMP-4 and BMP-7 are overexpressed in myeloma
cells, Noggin (BMP antagonist) is down regulated and
BMP-4 is up-regulated in prolactinoma, BMPR-II is up-
-regulated in bladder transitional cell carcinoma, BMP-2
is down regulated in the microadenomas of familiar ad-
enomatous polyposis patients, BMP-4 is down-regulated
in ACTH-secreting pituitary adenoma, BMP-3b and BMP-
-6 are silenced in lung cancers21. Also studies which have
been carried out to test the possible effects of BMPs on
tumor cell proliferation and apoptosis showed both growth
inhibitory and stimulatory effects. For example BMP-2
have stimulatory effect on lung cancer cells but inhibi-
tory effect on breast cancer cells14. Such inconsistencies
probably stem from the complex network of interactions
in the BMP signaling cascades and possibly from the tis-
sue specific differences.
Kwak et al. analyzed 185 kidney tumor specimens
and showed their positive expression for BMP-4 in 44.3%
specimens, BMP-6 in 20% and BMP-7 in 34.1%17. When
the clinical data were examined there was no statistically
significant association between BMP and age, ECOG
performance status and tumor stage. Disease-free sur-
vival was higher in patients with chromophobe subtype
of kidney cancer and BMP-7 positive expression. In this
subgroup of patients BMP-7 may be considered as a new
prognostic factor.
To our knowledge, our study was first which investi-
gated expression differences of BMP-7 and pSmad1/5/8
between normal kidney and RCC. Analysis showed that
kidney cancer tissue has lower expression of BMP-7 and
higher expression of pSmad1/5/8 than normal adult hu-
man kidney. The possible influence of BMP-7 in different
cancers was noticed. It was shown that BMP-7 have dose
dependent growth inhibition in thyroid carcinoma and
myeloma cell lines22,23. Also BMP-7 was highly expressed
in a breast cancer sample but not in normal breast
tissue13. Since in examined samples of RCC BMP-7 ex-
pression was decreased, but not statistically significant,
some effect of BMP-7 on RCC tumorigenesis probably ex-
ist but more proofs are needed. The further analysis with
RCC cancer lines can lighten possible stimulatory or in-
hibitory influence of BMP-7 on the cancer cells. It was al-
ready shown that Smad signaling enhances invasion and
bone metastasis of breast cancer24. Increased activity of
pSmad1/5/8 in our samples showed that BMP/Smad sig-
naling pathway is active in RCC.
Kim et al. investigated the role of BMP receptors in
renal cell carcinoma cells16. Results from his study sho-
wed that kidney cancer cells have decreased levels of
BMPR-II expression. This result was confirmed in our
study where decreased expression of BMPR-II in RCC
was noticed. Another detected receptor, BMPR-IB was
higher expressed in the RCC samples. Also BMP-6 has in
vitro, inhibitory effect on growth of tumor cells of RCC
but only in cancer cells with present BMPR-II16. Proba-
bly, decreased expression of BMPR-II have important
role in the carcinogenesis of kidney cancer. Alterations in
expression of BMP receptors and pSmad suggested that
BMP signaling pathway is affected in RCC.
In conclusion, our results showed that BMP-7, their
receptors and pSmad1/5/8 are present in the proximal
and distal part of nephron in the normal human kidney.
RCC have lower expression of BMP-7 and BMPR-II and
higher expression of BMPR-IB and pSmad1/5/8 than nor-
mal kidney. Obviously BMP and their signaling pathway
is involved in the kidney cancer carcinogenesis.
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IZRA@AJ KO[TANOG MORFOGENETSKOG PROTEINA-7, NJEGOVIH RECEPTORA I SMAD1/5/8 U
NORMALNOM BUBREGU I KARCINOMU BUBRE@NIH STANICA U ^OVJEKA
S A @ E T A K
Ko{tani morfogenetski proteini (BMPs) su citokini koji su va`ni za odr`avanje homeostaze bubrega ali tako|er ima-
ju ulogu u bubre`nim bolestima i karcinomu bubre`nih stanica (RCC)1–5. U posljednja tri desetlje}a u~estalost RCC
neprestano raste a ujedno se istra`uje i uloga razli~itih tumorskih biomarkera u RCC1. Analizirali smo izra`aj BMP-7,
BMP receptora (BMPR-IA, BMPR-IB, BMPR-II) kao i izra`aj proteina koji sudjeluju u signalnom putu (pSmad1/5/8).
Analizirali smo {esnaest uzoraka karcinoma i normalnog tkiva bubrega koriste}i se imunohistokemijom i Western blot
metodom. BMP-7, BMP receptori i pSmad1/5/8 bili su eksprimirani u svim dijelovima nefrona normalnog bubrega ali
najvi{e u stanicama proksimalnog tubula. U uzorcima karcinoma bubrega tako|er je zabilje`ena njihova ekspresija.
Usporedbom ekspresije izme|u rali~itih tkiva prikazali smo pove}anu ekspresiju BMPR-IB i pSmad 1/5/8 te smanjenu
ekspresiju BMP-7 i BMPR-II u RCC u odnosu na normalni bubreg. BMPR-IA je prikazan imunohistokemijskom meto-
dom ali je oslabljeni signal bio nedovoljan za analizu Western blotom. BMP-7, BMP receptori i pSmad1/5/8 su ekspri-
mirani u normalnom bubregu i u RCC. Prikazane promjene u izra`aju BMP-7, BMP receptora i pSmad1/5/8 u RCC
govore u prilog njihove mogu}e uloge u tumorigenezi karcinoma bubrega.
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